Targeting Drug Delivery to the Lungs by Inhalation
Most drugs targeted to the respiratory tract are used for their local action. For example, ephidrine for nasal decongestion, beta-2 agonists for bronchodilatation, and inhaled steroids to suppress the inflammation seen in asthmatic airways. Since the drug is delivered directly to its required site,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1994-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/S0962935194000724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559813774540800 |
|---|---|
| author | C. O'Callaghan |
| author_facet | C. O'Callaghan |
| author_sort | C. O'Callaghan |
| collection | DOAJ |
| description | Most drugs targeted to the respiratory tract are used for their
local action. For example, ephidrine for nasal decongestion, beta-2
agonists for bronchodilatation, and inhaled steroids to suppress the
inflammation seen in asthmatic airways. Since the drug is delivered
directly to its required site, only a small quantity is needed for
an adequate therapeutic response, and consequently there is a low
incidence of systemic side effects compared with oral or intravenous
administration. More recently, it has become apparent that the
lining of the respiratory tract, from nasal mucosa to airways and
alveoli, may be used for the absorption of a drug for its systemic
effect. This route of administration may be particularly attractive
if it avoids the metabolic destruction encountered when some drugs
are administered by alternative routes (for instance, peptides and
proteins are rapidly destroyed by peptidases when Oven by the oral
route). If there is a lack ofclinical response to an aerosolized
drug, it is important to question whether the drug has failed or
whether delivery to the site of action is inadequate. To deliver
therapeutic agents by inhalation to the lower respiratory tract,
inhaled drug particles must have appropriate aerodynamic
characteristics. In addition, the anatomy and pathophysiology of the
patient's respiratory tract, mode of inhalation through the
inhaler, and the characteristics of the inhalational device itself,
may significantly affect drug deposition. |
| format | Article |
| id | doaj-art-2175d5debf724257be9950e39b505c07 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 1994-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-2175d5debf724257be9950e39b505c072025-02-03T01:29:07ZengWileyMediators of Inflammation0962-93511466-18611994-01-0137S31S3310.1155/S0962935194000724Targeting Drug Delivery to the Lungs by InhalationC. O'Callaghan0Department of Child Health, School of Medicine, University of Leicester, Clinical Science Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, UKMost drugs targeted to the respiratory tract are used for their local action. For example, ephidrine for nasal decongestion, beta-2 agonists for bronchodilatation, and inhaled steroids to suppress the inflammation seen in asthmatic airways. Since the drug is delivered directly to its required site, only a small quantity is needed for an adequate therapeutic response, and consequently there is a low incidence of systemic side effects compared with oral or intravenous administration. More recently, it has become apparent that the lining of the respiratory tract, from nasal mucosa to airways and alveoli, may be used for the absorption of a drug for its systemic effect. This route of administration may be particularly attractive if it avoids the metabolic destruction encountered when some drugs are administered by alternative routes (for instance, peptides and proteins are rapidly destroyed by peptidases when Oven by the oral route). If there is a lack ofclinical response to an aerosolized drug, it is important to question whether the drug has failed or whether delivery to the site of action is inadequate. To deliver therapeutic agents by inhalation to the lower respiratory tract, inhaled drug particles must have appropriate aerodynamic characteristics. In addition, the anatomy and pathophysiology of the patient's respiratory tract, mode of inhalation through the inhaler, and the characteristics of the inhalational device itself, may significantly affect drug deposition.http://dx.doi.org/10.1155/S0962935194000724 |
| spellingShingle | C. O'Callaghan Targeting Drug Delivery to the Lungs by Inhalation Mediators of Inflammation |
| title | Targeting Drug Delivery to the Lungs by Inhalation |
| title_full | Targeting Drug Delivery to the Lungs by Inhalation |
| title_fullStr | Targeting Drug Delivery to the Lungs by Inhalation |
| title_full_unstemmed | Targeting Drug Delivery to the Lungs by Inhalation |
| title_short | Targeting Drug Delivery to the Lungs by Inhalation |
| title_sort | targeting drug delivery to the lungs by inhalation |
| url | http://dx.doi.org/10.1155/S0962935194000724 |
| work_keys_str_mv | AT cocallaghan targetingdrugdeliverytothelungsbyinhalation |